|
Market Closed -
Xetra
11:37:02 2026-10-07 am EDT
|
After hours 03:59:52 pm | |||
| 43.97 EUR | -1.06% |
|
43.93 | -0.09% |
| 06:04am | North Dakota rides soy boom, fueled by biofuels and China | RE |
| Oct. 05 | Zydus Launches First Generic of Bayer's Pulmonary Hypertension Drug in US | MT |
Business description: Bayer AG
- agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.7%).
Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).
Number of employees: 87,830
Sales by Activity: Bayer AG
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Crop Science | 20.22B | 25.18B | 23.29B | 22.31B | 21.68B |
Pharmaceuticals | 18.37B | 19.26B | 18.11B | 18.17B | 17.83B |
Consumer Health | 5.29B | 6.08B | 6.03B | 5.88B | 5.81B |
All Other | 203M | 219M | 239M | 328M | 303M |
Enabling Functions and Consolidation | -5M | -1M | -36M | -72M | -48M |
Geographical breakdown of sales: Bayer AG
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
United States | 13.4B | 15.68B | 14.59B | 14.8B | 15.1B |
Europe / Middle East / Africa (Excl. Germany & Switzerland) | 10.56B | 11.35B | 11.07B | 11B | 10.43B |
Brazil | 3.48B | 5.32B | 4.97B | 4.32B | 4.38B |
Asia / Pacific (Excl.China) | 4.99B | 5.19B | 4.74B | 4.47B | 4.05B |
China | 3.86B | 4.26B | 3.62B | 3.6B | 3.47B |
Latin America (Excl. Brazil) | 3.16B | 3.97B | 3.96B | 3.76B | 3.46B |
Germany | 2.54B | 2.48B | 2.45B | 2.41B | 2.58B |
North America (Excl.United States) | 1.56B | 1.89B | 1.67B | 1.68B | 1.63B |
Switzerland | 542M | 600M | 567M | 575M | 485M |
Executive Committee: Bayer AG
| Manager | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 60 | 2023-05-31 |
Judith Hartmann
DFI | Director of Finance/CFO | 57 | 2026-05-31 |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 59 | 2021-01-31 |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 57 | 2020-05-31 |
Philipp Blank
CMP | Compliance Officer | - | - |
Composition of the Board of Directors: Bayer AG
| Director | Title | Age | Since |
|---|---|---|---|
André van Broich
BRD | Director/Board Member | 56 | 2012-03-31 |
Heike Hausfeld
BRD | Director/Board Member | 61 | 2017-03-31 |
| Chairman | 68 | 2020-04-27 | |
Ertharin Cousin
BRD | Director/Board Member | 69 | 2019-09-30 |
| Director/Board Member | 69 | 2020-04-27 | |
Alberto Weisser
BRD | Director/Board Member | 70 | 2021-03-31 |
Andrea Sacher
BRD | Director/Board Member | 45 | 2020-08-31 |
Francesco Grioli
BRD | Director/Board Member | 54 | 2022-04-28 |
Claudia Schade
BRD | Director/Board Member | 47 | 2022-04-28 |
| Director/Board Member | 54 | 2022-04-28 |
Holdings: Bayer AG
| Name | Stocks | % | Valuation |
|---|---|---|---|
BAYER CROPSCIENCE LIMITED 71.43% | 32,102,999 | 71.43% | 1 339 M $ |
| 5,253,928 | 7.84% | 46 M $ | |
| 12,675,838 | 7% | 26 M $ | |
| 4,050,997 | 10.72% | 5 M $ | |
BOUNDLESS BIO, INC. 7.1% | 1,615,201 | 7.1% | 5 M $ |
BOUNDLESS BIO, INC. 5.96% | 2,809,848 | 5.96% | 1 M $ |
Company details: Bayer AG
Group companies: Bayer AG
| Name | Category and Sector |
|---|---|
Bayer CropScience, Inc. (Philippines)
 Bayer CropScience, Inc. (Philippines) Chemicals: AgriculturalProcess Industries Manufactures agricultural chemicals |
Chemicals: Agricultural
|
Bayer 04 Leverkusen Fußball GmbH
 Bayer 04 Leverkusen Fußball GmbH Movies/EntertainmentConsumer Services Operates as a sports clubs |
Movies/Entertainment
|
Elanco Animal Health GmbH
 Elanco Animal Health GmbH Pharmaceuticals: MajorHealth Technology Engages in researching and developing of antimicrobials, parasiticides and care products |
Pharmaceuticals: Major
|
Bayer Business & Technology Services LLC |
Information Technology Services
|
Bayer (Schweiz) AG
 Bayer (Schweiz) AG Pharmaceuticals: MajorHealth Technology Develops new molecules to improve the health of humans, animals and plants with products and solutions |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.06% | -8.30% | +58.28% | +1.22% | 49.18B | |
| +3.14% | +3.36% | +41.76% | +109.17% | 1,032B | |
| +1.84% | -1.93% | +37.46% | +63.77% | 614B | |
| +2.03% | +4.40% | +17.30% | +83.15% | 471B | |
| +0.75% | -1.58% | +63.24% | +36.86% | 350B | |
| +2.92% | +3.12% | +24.78% | +43.51% | 337B | |
| +2.42% | +0.05% | +14.13% | +36.19% | 268B | |
| +1.86% | -0.81% | -4.69% | +12.20% | 246B | |
| +2.67% | -2.21% | +39.47% | +51.80% | 218B | |
| +2.16% | -1.08% | +26.25% | +96.43% | 179B | |
| Average | +1.66% | -3.96% | +31.80% | +53.43% | 376.4B | |
| Weighted average by Cap. | +2.14% | -3.26% | +32.81% | +69.03% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BAYN Stock
- Company Bayer AG
Select your edition
All financial news and data tailored to specific country editions
